Dr. Satz, is a radiation physicist with more than 30 years of experience who
chairs the G-8 International Working Group of Nano safety and Nano security,
was previously the chairman of the Scientific Advisory Board of Florida
Atlantic University, the Board of the U.S. Industry Coalition, and Cygene Inc.
Dr. Satz has authored numerous journal articles and holds five issued and three
pending medically related U.S. patents. He is a leading authority on the
development of radiopharmaceuticals for tumor targeted radiation therapy.
Ms. Satz is a seasoned businesswoman that has worked hard to make a
difference in the world. Armed with degrees in both International Business and
Marketing Management her credibility and aptitude for developing professional
networks. She is a true entrepreneur engaged in multiple endeavors including
serving as CEO and Co-Founder of Advanced Innovative Partners. She has
served as a regulatory advisor and consultant for Johnson & Johnson as well
several foreign and domestic pharmaceutical manufacturers. Ms. Satz
successfully built a network of scientific experts, research organizations and
manufacturing partners building a robust pipeline of diagnostics and
Mr. King has held executive finance leadership positions at PepsiCo, Inc., J.H.
Cohn LLP, BDO Seidman, LLP, Peregrine Industries Inc., and Cavit Sciences,
Inc. His roles included operating publicly traded and development stage
biotech companies, structuring stock-based compensation plans, negotiating
all contracts, developing internal control policies, conducting control &
procedure evaluations, ensuring full compliance and complete disclosure,
raising private and institutional capital and preparation of SEC filings.
Dr. Zolata has extensive experience in radiopharmaceuticals and nuclear
medicine including, but not limited to: Production, Quality Control,
Preclinical evaluations; In vitro and In vivo, Tumor Targeting, Drug Delivery
and Controlled Release, Molecular Imaging, IND Protocols, Therapy Planning,
Quality Assurance, Regulatory affairs, Health Physics and Dosimetry
Calculation, Clean Room and cGMP regulations.
Mr. Waterbury is a Biologist with three decades of experience in life sciences
operations in academia and biotechnology companies. He specializes in
start-ups, laboratory and production planning, R&D and facility process
enablement/scale-up and consolidations. He authored a process patent and
over a dozen publications in genomics, mutation detection and immunology.
Greg has worked for investigators in Immunology and Genetics at Yale
University and Howard Hughes Medical Institute. He held a global EHS project
manager position at Life Technologies (now Thermo-Fisher), as well as key
project management position in startups spun out of Yale's tech transfer..
Dr. Mergui is a highly accomplished senior management professional in the nuclear medicine/biotech industry, boasting over 20 years of experience. Prior to her industry work, she served as a professor in Electrical Engineering at Florida International University for a decade and conducted research as a fellow at the Nuclear Research Center CNRS in Strasbourg, France. She held the position of Research Director at Capintec, Inc., and provided consultancy services to the biotech industry. Dr. Mergui has made significant contributions to the field through her publications on nuclear detectors, gamma imaging, and sensor technology. Additionally, she successfully managed nuclear medical imaging
research programs in collaboration with Berkeley National Laboratory. She holds certifications in Clinical Research CRA and Clinical Data Management CDM
Mr. Burnett has focused on strategic development with considerable
experience in cell and molecular cancer research, management of pilot
production and process development scale-up in diagnostic and drug
development in cGMP/GLP and CMC compliance. Mr. Burnett is also
instrumental in developing INDs, BLAs, ANDAs, 505(b)2s, CBE-30s, NDAs,
DMFs, formulated Orphan designation and Priority Review Voucher
applications for submission to the FDA utilizing the eCTD web portal. He
holds a Cell and Molecular Cancer Biochemistry honors bachelor’s degree.
Dr. Ortega is Medical Epidemiologist with emphasis in primary health care and
family medicine, with skills in design of preclinical and clinical trials, sample
size calculations, statistical analysis and other simulations of experiments,
leadership and teamwork, he is also skilled in site initiation, monitoring, and
close-out visits, as well as in maintaining study documentation and ensuring
the quality of data collected. He has experience in building positive
relationships with investigators, site staff, and study sponsors. With high
problem-solving capacity, to manage resources rationally, he is responsible
for overseeing the progress of several clinical trials and study protocols.
Mr. Castaño is a Colombian licensed attorney with extensive experience in the
legal field. He worked at Arrieta, Mantilla & Asociados, one of the leading law
firms in Colombia, notable for its representation of Colombia in the
International Court of Justice against Nicaragua. In addition to his experience
in commercial litigation and arbitration, Andrés has gained valuable
experience in international mergers and acquisitions (M&A) while working at
Lloreda Camacho & Co., one of the top full-service law firms in Colombia. He
has successfully assisted several startups with the private capitalization
process and corporate due diligence.
Eric Liu, M.D. is an oncological surgeon specializing in Neuroendocrine Tumors. An internationally recognized leader in theranostics, Dr. Liu is deeply involved in the R&D of new products in oncology. He served as Assistant Professor of Surgery and Radiology at Vanderbilt University where he established a Neuroendocrine Center and was the first to perform Gallium 68 PET/CT imaging in the United States. He currently heads the Neuroendocrine Institute in Denver, with the Rocky Mountain Cancer Centers, U.S. Oncology, and the Hospital Corporation of America.
Andre Abitbol, M.D. is a radiation oncologist, from the University of California San Francisco. Current director of Radiation Oncology and Miami Cancer Institute since 1982. Professor of radiation oncology, Florida International University Department of Radiation Oncology. Member of the Baptist Health South Florida Institutional Review Board (1991-current). Experience with multiple clinical trials with University of Miami collaboration phase I-II trials of combined radiation therapy and chemotherapy.
Richard P. Baum, M.D. was the Chairman and Clinical Director of the Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka. In 2013, Baum led the team that was the first in the world to use Lu-177 labeled PSMA for precision oncology of prostate cancer. His groundbreaking work in PRRT has provided the foundation for the advancement of tumor-targeted therapy. He has performed nearly 1,000 therapy cycles of PRRT, the largest series for a single center around the world.
Henry F. VanBrocklin, Ph.D, FSNMMI is Professor of Radiology and Biomedical Imaging at the University of California San Francisco (UCSF) and Director of Radiopharmaceutical Research in the Center for Functional and Molecular Imaging. His work in the field spans many radiopharmaceutical science disciplines from short-lived radioisotope production labeling chemistry strategies for new radiotracer preparations and applications. His current research interests include design of imaging agents targeting cancer cell surface markers.
Nirmal Kumar Ganguly, M.D., Ph.D. is President of Apollo Hospitals Educational and Research Foundation. He is a world-class microbiologist and Chairman of the High Level Advisory Committee to the Minister of Health on COVID-19. Ganguly is also Chairman of the Research Council of the Institute of Advanced Virology India National Academy of Medical Sciences, Chairman of Scientific Body of the Indian Pharmacopoeia Commission, Chairman, Expert Committee of the National Institute of Biologicals (NIB) guiding R&D activities and President of the Immunology Foundation of India.
Ruslan Medzhitov, Ph.D. is the Sterling Professor of Immunobiology at Yale University and Investigator and David Wallace Professor of Immunology at Howard Hughes Medical Institute. He is well known for the fundamental discoveries he made concerning the role that the toll-like receptors (TLRs) play in controlling adaptive immunity, infections, chronic inflammation and tumor growth. Recently his attention is focused on other aspects of the immune system, such as inflammation, tissue biology and the allergic response.
The Hon. Anne M. Harrington has over 45 years of experience in government, academia, and business, focusing principally on international security and nonproliferation issues. Her experience includes strategic planning; budget development and execution; project development, and management of budgets up to$2 billion per year. She is Internationally recognized expert on reducing the threat of weapons of mass destruction.
Dr. Tulip has extensive experience in radiopharmaceutical development and commercialization. Held positions of increasing responsibility at DuPont, BMS, Lantheus, Alseres, Navidea (Pres. & COO), and Fluoropharma (Pres. & CEO). Founder of MITA (Med. Imaging Tech. Assn.) PET Group and ExComm director for MITA.
Dr. Burns has over 30 years of operational and management expertise. He has developed a strong track record of success in strategic planning and growth initiatives. Dr. Burns was responsible for overseeing a team of economic, financial, accounting, and business analysts to a variety of companies with a net worth ranging from $100 to $300 million.
Mr. Crowe founded NuView Life Sciencces in 2005 and serves as its Chairman and Chief Executive Officer. Mr. Crowe’s experience includes start-up and early- stage healthcare company development, strategic planning, capital formation, M&A, and public offerings. Mr. Crowe’s career includes senior executive sales and management positions for domestic and multi-national healthcare.
Mr. Moran is experienced in the development, commercialization, and sales/management of pharmaceuticals and biotech companies. Mr. Moran spent the first 17 yrs of his career mainly at Merck & CO. and Pfizer. He secured funding for a range of healthcare-related tech and life science companies.
Mr. Morales has extensive research, development, design and OEM manufacturing of mobile terminal devices. Project management, strategy and tactics for the creation of new products, expert in the monitoring of tracking systems, service and engineering in Asia, of the mobile phone industry (Smartphones)